NICE has recommended rozanolixizumab for some adults living with generalised myasthenia gravis whose symptoms are not controlled by existing treatments, marking the first treatment the organisation has recommended for this condition. The decision, published on 29 April 2026, means the drug will be available on the NHS in England straight away through interim funding from the Innovative Medicines Fund.
A rare autoimmune condition with unpredictable flare-ups
Generalised myasthenia gravis is described by NICE as a rare, long-term autoimmune condition that causes muscle weakness and extreme tiredness. It can affect breathing, speech, swallowing, eyesight and movement, and symptoms can flare up unpredictably, often leading to repeated hospital visits. NICE also said there is currently no cure.
According to the guidance, the recommendation could help around 800 adults in England. The treatment is intended to reduce symptoms and improve day-to-day quality of life for people whose disease remains uncontrolled on current therapy.
What the new recommendation means for patients
NICE said the draft recommendation is an important step forward for people living with the condition. It also noted that better symptom control may allow some patients to reduce long-term steroid use, which could lower the risk of side effects. The drug has been recommended for adults with generalised myasthenia gravis whose symptoms are not controlled by existing treatments.
The decision comes at a time when NICE has been issuing a series of treatment recommendations for serious and chronic conditions, including recent guidance for other diseases such as chronic lymphocytic leukaemia and multiple myeloma. In this case, however, the focus is on a rare neuromuscular disorder that can significantly disrupt everyday life.
Access on the NHS begins immediately
Because the medicine will be available through interim funding from the Innovative Medicines Fund, eligible patients in England can access it without delay while the wider process continues. NICE said the recommendation was published in final draft guidance on 29 April 2026.
The move adds a new option for clinicians treating a condition that can be difficult to manage and whose symptoms can vary from day to day. For patients, the hope is that a targeted treatment will bring more stable control and reduce the burden of repeated flare-ups.
More details are available from NICE’s announcement at NICE.
Sursa foto: Imagine generată AI
